Skip to content

Clinical Study on â??Ortho21â?¿ of OnTop Vedics as a Pain Relief Oil.

An Open Label, Prospective, Randomised, Comparative, Two Arm Clinical Study to Evaluate the Effectiveness, Safety and Tolerability of â??Ortho21â?¿ of OnTop Vedics as a Topical Treatment for Relief from Chronic and Acute Pain in Adult Subjects.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034690
Enrollment
40
Registered
2021-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M255- Pain in joint

Interventions

Intervention1: Ortho21 Advanced Pain Relief Oil: Dose: Desired Quantity of Oil Dosage: Treatment Arm I - Once a Day, take a small quantity of Ortho21 and massage gently topically on the area with pain

Sponsors

OnTop Vedics A Division of OnTop Pharmaceuticals
Lead Sponsor
Aurous HealthCare Research and Development India Private Limited
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult subjects between the ages of 21 and 65 years (Both ages and all genders inclusive) with chronic pain attributed to arthritis and or acute pains such as sprains, muscle aches. 2. Subjects who are willing to abstain from use of herbal, allopathic or other nutritional supplements that are indicated at improving joint pain, joint and muscle health. 3. Subjects who are willing to abstain from use of any topical ointment, cream etc that are indicated for mitigating pain and aches. 4. Subjects who have a pain score of 2-5 on a 10 point NRS at the time of screening in a minimum of one joint. 5. Subject who are willing to give informed consent for participation, able to comprehend and understand the responsibilities during screening and treatment period. 6. Subjects who are willing not to participate in any other clinical trial during participation in the current trial.

Exclusion criteria

Exclusion criteria: 1. Subjects with known hypersensitivity to the ingredients of the investigational product. 2. Subjects who have an active infection, disease or disorder that will prevent them from fully satisfying the responsibilities of the study. 3. Subjects with history of seizures, uncontrolled diabetes, hypertension or major cardiac illness like congestive heart failure etc. 4. Subjects on remission from cancer of any type less than 5 years at the time of screening. 5. Subjects who are planning a pregnancy and - or currently breastfeeding. 6. Subjects who have participated in a clinical study less than 1 month before screening. 7. Any significant medical condition -e.g., significant psychiatric or neurological disorders, active alcohol or drug abuse, etc -, any medical condition that is unstable or poorly controlled or other factor -eg., planned relocation - that investigator felt would interfere with study evaluations and study participation. 8. Subjects who are unable to comprehend the responsibilities and adhere to the stipulations of the protocol. 9. Subjects, who in the opinion of the Investigator are not eligible for enrolment in the study.

Design outcomes

Primary

MeasureTime frame
Brief Pain Inventory -Short Form - : Improvement by greater than or equal to 50 percent: Sum of Pain Intensity Difference Brief Pain Inventory - Short Form - : Score of greater than or equal to 50 percent: Relief from treatment Brief Pain Inventory - Short Form- : Improvement by greater than or equal to 50 percent: Pain Interference IP Feedback Questionnaire - IPFBQ - : Total score of greater than or equal to 20 Timepoint: Brief Pain Inventory - Short Form - : Day 1, Day 30 IP Feedback Questionnaire - IPFBQ - : Day 30

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactDr VTSriraam

Aurous HealthCare Research and Development India Private Limited

md@auroushealthcare.com9840909155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026